Sigfox and INDIGO® weel Join Forces to Promote 100% Connected Urban Mobility
Self-service bicycle fleet INDIGO® weel, a subsidiary of the INDIGO group, has been fitted with sensors, supported by Sigfox's 0G network, that can accurately pinpoint their location at any given time. As the number of shared vehicles in circulation increases, this integration of Sigfox technology will help to better protect the fleet from damage or theft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190712005234/en/
Photo : INDIGO weel
The Sigfox solution offers multiple benefits for INDIGO® weel:
- An easier customer journey: pinpointing the location of bicycles more accurately, in real-time, allows users of the service to locate bikes on the street faster and more easily;
- Better protection against damage and theft due to a greater understanding of high-risk areas;
- A reduction in repair costs thanks to reusable sensors that can easily be transferred from a damaged bike to a new one;
- Flexible technology that can be used in other markets, if the INDIGO® weel service expands internationally, courtesy of Sigfox's global 0G network that spans some sixty countries;
- Durable sensors that consume very little energy
Together, INDIGO® weel and Sigfox are providing a solution to the public that addresses a number of the current challenges facing mobility services. Population growth in cities, as well as increasing environmental awareness now requires us to reconsider the way we move around each day. Innovative private sector services are therefore needed, in order to be able to offer a wider range of mobility solutions to the public. These must, however, complement the existing public transport offering, with those in charge working closely with city authorities in metropolitan areas.
New mobility solutions have been changing the face of city centre travel in recent years, but in order to be fully effective, they still have to find their place in the landscape. In this new market, INDIGO® weel is positioning itself as an innovative brand, keen to constantly evolve and partner with other forward-thinking businesses to do that.
One example of this innovation prompts users to take a photo at the end of their bike rental period to certify that the vehicle is in good parking condition. Each photo is then processed by customer services and users who comply with national, local and ‘Our Service’ rules will gain access to more advantageous offers.
Any change involves some risks and challenges, but the association between Sigfox and INDIGO® weel is already reaping benefits. Since the fleet was equipped with connected sensors, improvements to the geolocation system has reduced bicycle damage by a factor of 4. In addition, bicycle repair/replacement is now also faster than in the past. These improvements benefit INDIGO® weel, but also, more broadly, the inhabitants of cities where the connected vehicles are available, providing them with a high quality, sustainable service.
Jean Gadrat, CEO of INDIGO® weel, explains: "Public stakeholders and users today want a wider range of mobility solutions at their disposal and innovation in the sector that will help shape the city of tomorrow. It is in this context that we enter the market as a private company, in order to provide citizens with a respectful, complementary offering. INDIGO® weel wants to be a responsible player in the urban mobility market. We work tirelessly to offer the best possible service to our customers and make our products more efficient, which is why we have chosen to embed Sigfox’s technology into the fleet. It allows us to strengthen the sustainability of our offering and fully integrate our vehicles into the urban ecosystem.”
Patrick Cason, General Manager at Sigfox France, said: "Through this collaboration, we are once again demonstrating the many ways in which our 0G network can be used to serve society. The challenges of mobility, especially in cities, are many and well known. Faced with increasingly populated cities and an environmental awareness that can no longer be ignored, we must create new, more sustainable mobility solutions. Free floating bike is one of them. We are working with INDIGO® weel to provide the best service possible to meet the needs of citizens and to ensure that free floating bike finds its place in the city.”
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.
Today, the network is available in 60 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.
Antoine Mège, PR & Content Manager
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines13.11.2019 11:29:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that NHS Wales has accepted an offer for all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England. This means that once the contract is finalized, patients with CF in Wales ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can access ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations can access SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor in the coming weeks. The agreement also offers expanded access to KALYDECO ® (ivacaftor) to include those patients ages 12 months and older who have one of the nine licensed gating mutations. “Today’s a
Software Testing and Digital Transformation Partners Recognized at 2019 Tricentis Partner Awards13.11.2019 11:00:00 CET | Press release
Tricentis, the cloud’s #1 Continuous Testing Platform, today recognized top-performing partners from around the world during Tricentis Accelerate 2019 in Vienna, Austria. In its 5th year, the Tricentis Partner Awards recognize organizations for accelerating digital transformation across the enterprise. Award winners were selected from more than 300 different partners worldwide based on their collaboration with Tricentis, customers, and their advocacy for Tricentis’ automation methodologies. “Tricentis partners are leading the way for organizations to innovate faster, reduce business risk, and optimize cost,” said Alan Ota, Senior Vice President of Strategic Alliances, Tricentis. “Our partners are instrumental to our business and are focused on delivering the best in-class testing solutions to our joint customers. Our tremendous growth would not be possible without our global partners. We’re proud to acknowledge the achievements made by our partners in 2019 and look forward to continuin
Applicaster Appoints Jason Johns as Vice President of Sales, EMEA and APAC13.11.2019 10:00:00 CET | Press release
Applicaster, the company simplifying the lifecycle management of direct-to-consumer media applications, today announced the appointment of Jason Johns as Vice President of Sales, EMEA and APAC. In his role, Johns will oversee Applicaster’s EMEA and APAC commercial and go-to-market strategies. “There is an incredible amount of opportunity in the media app market,” said Johns. “Because of our ability to enable frictionless growth for customers, we’re very well positioned to take advantage of this opportunity. Beyond the market opportunity, I was attracted to Applicaster because of the company’s customer-first culture plus its ability and desire to drive value lead engagements. Few businesses buy technology without a clear understanding of the business case and full transparency of the cost-of-ownership around their technology investments - Applicaster understands this and provides flexible commercial models that scale and can easily be upgraded and expanded as business requirements evolv
Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy13.11.2019 09:00:00 CET | Press release
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Rucaparib will soon be available as an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.3 Rucaparib is indicated for eligible patients regardless of BRCA status, which means it can be prescribed for women who harbor a BRCA mutation or who are BRCA wild-type.3 “We very much welcome the arrival of the PARP inhibitor rucaparib, which offers a new treatment option after surgery and two lines of chemotherapy to all eligible women affected by relapsed ovarian cancer,” declared Nicoletta Cerana, National President of Acto Onlus, the number one Italian network of patient associations involved in the fight against ovarian cancer and gynecological tumors. “Ovarian cancer is a highly lethal
Traxens Presents Solutions for Port Industry at Smart Ports Barcelona13.11.2019 07:30:00 CET | Press release
Traxens, a company providing high-value data and services for the supply chain industry, announces today that it will present its smart asset tracking solutions at the Smart Ports Barcelona event, Smart Ports, Piers of the Future, November 19 to 21. Its tailored Industrial Internet of Things (IIoT) solutions are specifically designed to meet the needs of the port industry by providing near real-time insight into the end-to-end global supply chain. Traxens’ solution provides comprehensive, precise and timely data on cargo, through tracking logistic assets in transit anywhere in the world. Traxens’ patented breakthrough Internet of Things (IoT) technology brings improved efficiency and security, greater transparency and enhanced asset utilization whilst opening up new opportunities for all actors involved in the global supply chain. With Traxens’ solutions, ports can improve their efficiency and the interoperability of the systems with a trusted third party. For example, the Cargo Commun
PMC Group Announces Agreement to Acquire Lanxess’ Organotin Specialties Business13.11.2019 06:30:00 CET | Press release
PMC Group N.A., Inc. ("PMC") and Lanxess Organometallics GmbH are pleased to announce that the parties have reached an agreement whereby PMC’s European subsidiary will acquire the organotin specialties product line (the “Business”) from Lanxess. The transaction is scheduled to close by year end, subject to customary closing conditions. The Business includes Lanxess’ global organotin catalyst, organotin specialties and intermediates product lines. The transaction includes a toll manufacturing agreement under which Lanxess will continue to manufacture certain products post-closing for PMC at its Bergkamen, Germany organometallics manufacturing facility. Mr. Debtosh Chakrabarti, President of PMC said, “This acquisition represents PMC’s continuing commitment to the organotin industry and is synergistic to our existing organometallics and catalyst businesses. We believe that the customer base of the Business as well as all of PMC’s customers will benefit significantly from combining the tec